4-methyl-3-phenyltetrahydrofuran | 102503-71-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-methyl-3-phenyltetrahydrofuran
• 英文别名: 3-methyl-4-phenyltetrahydrofuran；3-Methyl-4-phenyloxolane
• CAS: 102503-71-9；102503-72-0
• 化学式: C₁₁H₁₄O
• 分子量: 162.232
• InChiKey: KFOLRMJLSWVNEG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  alpha-硝基苯乙烯 在 偶氮二异丁腈 三正丁基氢锡 作用下， 以 苯 为溶剂， 反应 2.0h， 生成 4-methyl-3-phenyltetrahydrofuran
  参考文献：
  名称：

  脂肪族硝基化合物的脱氮加氢和脂肪族硝基化合物作为自由基前体的新用途

  摘要：

  在氢化三丁基锡氢化物处理中，脂肪族硝基被氢取代，氢化三丁基锡通过自由基链过程进行。由于硝基被选择性地反硝化并且其他可还原基团不受氢化三丁基锡的影响，因此该反应可用作从多官能化合物中去除硝基的方法。通过脱硝产生的自由基中间体也可用于碳-碳键形成反应。

  DOI：

  10.1016/s0040-4020(01)97180-7

文献信息

• [EN] ERK INHIBITORS<br/>[FR] INHIBITEURS D'ERK
  申请人：MERCK SHARP & DOHME

  公开号：WO2016100050A1

  公开（公告）日：2016-06-23

  The present invention provides a compound of Formula (I) or the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are ERK2 inhibitors. The invention also provides a pharmaceutical composition comprising an effective amount of at least one compound of Formula (I) and a pharmaceutically acceptable carrier. The invention also provides a pharmaceutical composition comprising an effective amount of at least one compound of Formula (I) and an effective amount of at least one other pharmaceutically active ingredient (such as, for example, a chemotherapeutic agent), and a pharmaceutically acceptable carrier.

  本发明提供了一种化合物(I)或其药学上可接受的盐、酯和前药，这些化合物是ERK2抑制剂。该发明还提供了一种包括至少一种化合物(I)和药学上可接受的载体的有效量的药物组合物。该发明还提供了一种包括至少一种化合物(I)的有效量和至少一种其他药学活性成分的有效量（例如，化疗药物等）以及药学上可接受的载体的药物组合物。
• [EN] 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS<br/>[FR] DÉRIVÉS DE 1,2,4-TRIAZOLO[4,3-A]PYRIDINE ET LEUR UTILISATION EN TANT QUE MODULATEURS ALLOSTÉRIQUES POSITIFS DES RÉCEPTEURS MGLUR2
  申请人：JANSSEN PHARMACEUTICALS INC

  公开号：WO2012062750A1

  公开（公告）日：2012-05-18

  The present invention relates to novel triazolo [4,3-a]pyridine derivatives of Formula (I), wherein all radicals are as defined in the claims. The compounds according to the invention are positive allosteric modulators of the metabotropic glutamate receptor subtype 2 ("mGluR2"), which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds for the prevention or treatment of neurological and psychiatric disorders and diseases in which mGluR2 is involved.

  本发明涉及式(I)的新三唑[4,3-a]吡啶衍生物，其中所有基团均如权利要求中所定义。根据发明的化合物是代谢型谷氨酸受体2型("mGluR2")的正变构调节剂，用于治疗或预防与谷氨酸功能障碍相关的神经和精神障碍以及涉及mGluR2亚型的代谢型受体的疾病。本发明还涉及包含这些化合物的药物组合物，制备这些化合物和组合物的方法，以及使用这些化合物预防或治疗涉及mGluR2的神经和精神障碍和疾病。
• Tetrahydrofuran Derivatives from Epoxides <i>via</i> Group Transfer Cyclization or Reductive Radical Cyclization of Organotellurium and Organoselenium Intermediates
  作者：Lars Engman、Vijay Gupta

  DOI：10.1021/jo961578n

  日期：1997.1.1

  undergo group transfer cyclization to afford 2-substituted 4-[(aryltelluro)methyl]tetrahydrofurans (cis/trans = 1/3-1/10). The aryl beta-(prop-2-ynyloxy)alkyl tellurides similarly afforded 2-substituted 4-[(aryltelluro)methylene]tetrahydrofurans with an E/Z-ratio close to unity. The beta-(allyloxy)alkyl aryl selenides and aryl beta-(prop-2-ynyloxy)alkyl selenides failed to undergo group transfer cyclization

  单取代的环氧化物从空间上受阻最小的一面通过苯碲酸根和苯硒酸根试剂进行区域特异性开环，分别得到芳基β-羟烷基碲化物和硒化物。通过在四氢呋喃中用烯丙基溴/氢化钠处理将这些材料进行O-烯丙基化，并在与炔丙基溴/氢化钠反应时将O-prop-2-炔化。在含有40 mol％的六丁基二锡的苯中进行光解后，发现β-（烯丙氧基）烷基芳基碲化物经历了基团转移环化，从而获得了2-取代的4-[（（芳基碲基）甲基]四氢呋喃（顺式/反式= 1 / 3- 1/10）。芳基β-（丙-2-炔氧基）烷基碲化物类似地得到E / Z比接近于1的2-取代的4-[（芳基碲基）亚甲基]四氢呋喃。β-（烯丙氧基）烷基芳基硒化物和芳基β-（丙-2-基氧基氧基）烷基硒化物未进行基团转移环化。在氢化三丁基锡和2,2'-偶氮二异丁腈的存在下，发现前一种化合物以高收率进行还原性自由基环化，得到2-取代的4-甲基四氢呋喃（顺式/反式= 1 / 3-1
• Sulfonamides and Pharmaceutical Compositions Thereof
  申请人：Estep Kimberly Gail

  公开号：US20100035865A1

  公开（公告）日：2010-02-11

  The invention is directed to a class of compounds, including the pharmaceutically acceptable salts of the compounds, having the structure of formula (I), as defined in the specification. The invention is also directed to compositions containing the compounds of formula (I).

  本发明涉及一类化合物，包括化合物的药学上可接受的盐，具有公式(I)所定义的结构，本发明还涉及含有公式(I)化合物的组合物。
• Microwave-Assisted Group-Transfer Cyclization of Organotellurium Compounds
  作者：Cecilia Ericsson、Lars Engman

  DOI：10.1021/jo040155f

  日期：2004.7.1

  Primary- and secondary-alkyl aryl tellurides, prepared by arenetellurolate ring-opening of epoxides/O-allylation, were found to undergo rapid (3 - 10 min) group-transfer cyclization to afford tetrahydrofuran derivatives in 60-74% yield when heated in a microwave cavity at 250 degreesC in ethylene glycol or at 180 degreesC in water. To go to completion, similar transformations had previously required extended photolysis in refluxing benzene containing a substantial amount of hexabutylditin. The only drawback of the microwave-assisted process was the loss in diastereoselectivity which is a consequence of the higher reaction temperature. Substitution in the Te-aryl moiety of the secondary-alkyl aryl tellurides (4-OMe, 4-H, 4-CF3) did not affect the outcome of the group-transfer reaction in ethylene glycol. However, at lower temperature, using water as a solvent, the CF3 derivative failed to react. The microwave-assisted group-transfer cyclization was extended to benzylic but not to primary- and secondary-alkyl phenyl selenides.